PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18509327-2 2009 Among the transfected models investigated, OATP1B3 (SLCO1B3) was identified as the most efficient influx transporter for docetaxel. Docetaxel 121-130 solute carrier organic anion transporter family member 1B3 Homo sapiens 43-50 22711709-2 2012 We hypothesized that (i) liver uptake of docetaxel is mediated by the polymorphic solute carriers OATP1B1 and OATP1B3 and (ii) inherited genetic defects in this process may impair systemic drug elimination. Docetaxel 41-50 solute carrier organic anion transporter family member 1B3 Homo sapiens 110-117 22711709-5 2012 RESULTS: Docetaxel was found to be a substrate for OATP1B1, OATP1B3, and Oatp1b2 but was not transported by OATP1B1*5. Docetaxel 9-18 solute carrier organic anion transporter family member 1B3 Homo sapiens 60-67 21468756-0 2011 The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Docetaxel 143-152 solute carrier organic anion transporter family member 1B3 Homo sapiens 55-62 21468756-1 2011 PURPOSE: This exploratory study aimed to explain the interindividual variabilities of docetaxel pharmacokinetics and pharmacodynamics in Asian nasopharyngeal carcinoma patients (n = 54) through the genotyping of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 genes. Docetaxel 86-95 solute carrier organic anion transporter family member 1B3 Homo sapiens 252-259 21468756-5 2011 RESULTS: Patients homozygous for the variant allele (GG) of SLCO1B3 rs11045585 (IVS12-5676A > G) had significantly higher area under the plasma concentration-time curve of docetaxel (P = 0.026) and lower clearance (P = 0.036) compared to patients with AA/AG genotypes. Docetaxel 175-184 solute carrier organic anion transporter family member 1B3 Homo sapiens 60-67 21995462-0 2012 Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Docetaxel 43-52 solute carrier organic anion transporter family member 1B3 Homo sapiens 13-20 21995462-1 2012 WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: SLCO1B3 is an influx transporter located at the hepatocyte basolateral membrane and it is involved in the uptake of a broad range of drug substrates including docetaxel. Docetaxel 201-210 solute carrier organic anion transporter family member 1B3 Homo sapiens 42-49 21995462-3 2012 Docetaxel displays a wide interindividual variability in its pharmacokinetics and pharmacodynamics and an understanding of SLCO1B3 pharmacogenetics might provide clinical benefits in guiding docetaxel dosing. Docetaxel 191-200 solute carrier organic anion transporter family member 1B3 Homo sapiens 123-130 21995462-8 2012 This study suggests that the comprehensive screening and haplotypic linkage analysis of SLCO1B3 can better elucidate its pharmacogenetic effects on interpatient variability of docetaxel and other putative drug substrates. Docetaxel 176-185 solute carrier organic anion transporter family member 1B3 Homo sapiens 88-95 21995462-15 2012 The SLCO1B3 haplotypic region comprising seven htSNPs was found to be significantly associated with docetaxel clearance (P= 0.003). Docetaxel 100-109 solute carrier organic anion transporter family member 1B3 Homo sapiens 4-11 21995462-20 2012 CONCLUSIONS: This study highlights the importance of SLCO1B3 polymorphic variations in influencing docetaxel disposition in nasopharyngeal carcinoma patients. Docetaxel 99-108 solute carrier organic anion transporter family member 1B3 Homo sapiens 53-60 21468756-8 2011 CONCLUSIONS: This study suggests that the cooperative influence of functional polymorphisms in SLCO1B3 and ABCB1 genes may be responsible for the interindividual variability in docetaxel disposition in Asian nasopharyngeal cancer patients. Docetaxel 177-186 solute carrier organic anion transporter family member 1B3 Homo sapiens 95-102 18509327-2 2009 Among the transfected models investigated, OATP1B3 (SLCO1B3) was identified as the most efficient influx transporter for docetaxel. Docetaxel 121-130 solute carrier organic anion transporter family member 1B3 Homo sapiens 52-59 27537383-7 2016 RESULTS: Organic anion-transporting polypeptide (SLCO1B3), an influx transporter of docetaxel, was significantly downregulated in PC346C-DOC tumours. Docetaxel 84-93 solute carrier organic anion transporter family member 1B3 Homo sapiens 49-56 18082941-5 2008 Antineoplastic screening demonstrated that five candidates agents, docetaxel, actinomycin D, mitoxantrone, paclitaxel, and SN-38, exhibited potent inhibitory effects on OATP1B3-mediated transport of CDCA-NBD. Docetaxel 67-76 solute carrier organic anion transporter family member 1B3 Homo sapiens 169-176 30782852-2 2019 In the past decade, OATPs, primarily OATP1A2, OATP1B1, and OATP1B3, have emerged as potential mediators of chemotherapy disposition, including drugs such as methotrexate, doxorubicin, paclitaxel, docetaxel, irinotecan and its important metabolite 7-ethyl-10-hydroxycamptothecin, and certain tyrosine kinase inhibitors. Docetaxel 196-205 solute carrier organic anion transporter family member 1B3 Homo sapiens 59-66 18294295-0 2008 Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Docetaxel 63-72 solute carrier organic anion transporter family member 1B3 Homo sapiens 40-47 18294295-5 2008 The combined analysis indicated a significant association of rs12762549 in ABCC2 (P = 0.00022) and rs11045585 in SLCO1B3 (P = 0.00017) with docetaxel-induced leukopenia/neutropenia. Docetaxel 140-149 solute carrier organic anion transporter family member 1B3 Homo sapiens 113-120 18294295-7 2008 This prediction system correctly classified 69.2% of severe leukopenia/neutropenia and 75.7% of non-leukopenia/neutropenia into the respective categories, indicating that SNPs in ABCC2 and SLCO1B3 may predict the risk of leukopenia/neutropenia induced by docetaxel chemotherapy. Docetaxel 255-264 solute carrier organic anion transporter family member 1B3 Homo sapiens 189-196 33649517-2 2021 In this study, we aimed to assess the functional significance of 14 polymorphisms in the CYP3A, CYP1B1, ABCB1, ABCC2, and SLCO1B3 genes for the pharmacokinetics and pharmacodynamics of oral docetaxel, co-administered with ritonavir. Docetaxel 190-199 solute carrier organic anion transporter family member 1B3 Homo sapiens 122-129 32989230-5 2020 Furthermore, testosterone competed with docetaxel for uptake by the drug transporter OATP1B3. Docetaxel 40-49 solute carrier organic anion transporter family member 1B3 Homo sapiens 85-92 27400856-5 2017 In the largest combined sample to date, we identified a novel association with rs149104283 (odds ratio (OR)=4.32, P=1.79 x 10-8), intronic to transcripts of SLCO1B3 and SLCO1B7, members of a family of hepatic transporter genes previously implicated in adverse drug reactions including simvastatin-induced myopathy and docetaxel-induced neutropenia. Docetaxel 318-327 solute carrier organic anion transporter family member 1B3 Homo sapiens 157-164 27452633-0 2016 Pharmacokinetic effects of curcumin on docetaxel mediated by OATP1B1, OATP1B3 and CYP450s. Docetaxel 39-48 solute carrier organic anion transporter family member 1B3 Homo sapiens 70-77 27452633-6 2016 Curcumin exhibited potent inhibition on OATP1B1 and OATP1B3-mediated docetaxel uptake with IC50 values of 3.81 +- 1.19 muM and 33.70 +- 1.22 muM, respectively. Docetaxel 69-78 solute carrier organic anion transporter family member 1B3 Homo sapiens 52-59 27452633-8 2016 The preclinical and clinical improved docetaxel"s therapeutic efficacy when co-administrated with curcumin may be due to the inhibition of curcumin on OATP1B1, OATP1B3 and HLMs activities. Docetaxel 38-47 solute carrier organic anion transporter family member 1B3 Homo sapiens 160-167 27537383-10 2016 Overexpression of SLCO1B3 showed higher sensitivity to docetaxel and cabazitaxel. Docetaxel 55-64 solute carrier organic anion transporter family member 1B3 Homo sapiens 18-25 27537383-11 2016 CONCLUSIONS: The SLCO1B3 determines intracellular concentrations of docetaxel and cabazitaxel and consequently influences taxane efficacy. Docetaxel 68-77 solute carrier organic anion transporter family member 1B3 Homo sapiens 17-24 25695959-3 2015 By screening an array of drug uptake transporters in HeLa cells using a recombinant vaccinia-based method, five organic anion-transporting polypeptides (OATP) capable of docetaxel uptake were identified: OATP1A2, OATP1B1, OATP1B3, OATP1C1, and Oatp1b2. Docetaxel 170-179 solute carrier organic anion transporter family member 1B3 Homo sapiens 222-229 25648089-10 2015 CONCLUSION: Our data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy. Docetaxel 112-121 solute carrier organic anion transporter family member 1B3 Homo sapiens 54-61 25648089-10 2015 CONCLUSION: Our data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy. Docetaxel 163-172 solute carrier organic anion transporter family member 1B3 Homo sapiens 54-61 25695959-5 2015 An assessment of polymorphisms (SNPs) in SLCO1B1 and SLCO1B3 revealed that a number of OATP1B1 and OATP1B3 variants were associated with impaired docetaxel transport. Docetaxel 146-155 solute carrier organic anion transporter family member 1B3 Homo sapiens 99-106 25054314-0 2014 Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity. Docetaxel 64-73 solute carrier organic anion transporter family member 1B3 Homo sapiens 44-51 25054314-2 2014 Our previous report indicated that the prevalence of severe docetaxel-induced neutropenia is significantly associated with genetic polymorphisms in solute carrier organic anion transporter 1B3 (SLCO1B3) (encoding organic anion-transporting polypeptide 1B3 (OATP1B3)) and ATP-binding cassette subfamily C2 (ABCC2) (encoding multidrug-resistant-associated protein 2 (MRP2)). Docetaxel 60-69 solute carrier organic anion transporter family member 1B3 Homo sapiens 148-192 25054314-2 2014 Our previous report indicated that the prevalence of severe docetaxel-induced neutropenia is significantly associated with genetic polymorphisms in solute carrier organic anion transporter 1B3 (SLCO1B3) (encoding organic anion-transporting polypeptide 1B3 (OATP1B3)) and ATP-binding cassette subfamily C2 (ABCC2) (encoding multidrug-resistant-associated protein 2 (MRP2)). Docetaxel 60-69 solute carrier organic anion transporter family member 1B3 Homo sapiens 194-201 25054314-2 2014 Our previous report indicated that the prevalence of severe docetaxel-induced neutropenia is significantly associated with genetic polymorphisms in solute carrier organic anion transporter 1B3 (SLCO1B3) (encoding organic anion-transporting polypeptide 1B3 (OATP1B3)) and ATP-binding cassette subfamily C2 (ABCC2) (encoding multidrug-resistant-associated protein 2 (MRP2)). Docetaxel 60-69 solute carrier organic anion transporter family member 1B3 Homo sapiens 213-255 25054314-2 2014 Our previous report indicated that the prevalence of severe docetaxel-induced neutropenia is significantly associated with genetic polymorphisms in solute carrier organic anion transporter 1B3 (SLCO1B3) (encoding organic anion-transporting polypeptide 1B3 (OATP1B3)) and ATP-binding cassette subfamily C2 (ABCC2) (encoding multidrug-resistant-associated protein 2 (MRP2)). Docetaxel 60-69 solute carrier organic anion transporter family member 1B3 Homo sapiens 257-264 25054314-5 2014 To further characterize a quantitative impact of OATP1B3 and MRP2 on neutropenia, we used an in silico simulation of the neutrophil count in docetaxel-treated subjects with functional changes in OATP1B3 and MRP2 in a pharmacokinetic/pharmacodynamic model. Docetaxel 141-150 solute carrier organic anion transporter family member 1B3 Homo sapiens 195-202 25054314-6 2014 The clinically reported odds ratios for docetaxel-induced neutropenia risk were explained by the decreased function of OATP1B3 and MRP2 to 41 and 32%, respectively. Docetaxel 40-49 solute carrier organic anion transporter family member 1B3 Homo sapiens 119-126 25054314-7 2014 These results suggest that reduced activities of OATP1B3 and MRP2 associated with systemic exposure and local accumulation in bone marrow cells, respectively, account for the docetaxel-induced neutropenia observed clinically. Docetaxel 175-184 solute carrier organic anion transporter family member 1B3 Homo sapiens 49-56 24825069-0 2015 Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Docetaxel 83-92 solute carrier organic anion transporter family member 1B3 Homo sapiens 15-22 24825069-3 2015 Docetaxel was administered to Oatp1a/1b knockout and liver-specific humanized OATP1B1, OATP1B3 and OATP1A2 transgenic mice. Docetaxel 0-9 solute carrier organic anion transporter family member 1B3 Homo sapiens 87-94 24825069-8 2015 Most importantly, liver-specific expression of each of the human OATP1B1, OATP1B3 and OATP1A2 transporters provided a nearly complete rescue of the increased plasma levels of docetaxel in Oatp1a/1b-null mice after intravenous administration. Docetaxel 175-184 solute carrier organic anion transporter family member 1B3 Homo sapiens 74-81 23188068-0 2013 The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Docetaxel 60-69 solute carrier organic anion transporter family member 1B3 Homo sapiens 47-54 23188068-1 2013 Docetaxel-related neutropenia was associated with polymorphisms in the drug transporters ABCC2 and SLCO1B3 in Japanese cancer patients. Docetaxel 0-9 solute carrier organic anion transporter family member 1B3 Homo sapiens 99-106